Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x100px
Organisation › Details

Vivet Therapeutics SAS

Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain. Vivet’s lead program, VTX-801, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) and the European Commission (EC). This rare genetic disorder is caused by mutations in the gene encoding the ATP7B protein, which reduces the ability of the liver and other tissues to regulate copper levels causing severe hepatic damage, neurologic symptoms and potentially death. Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partners. *


Period Start 2016-07-26 established
  Group Vívet Therapeutics (Group)
Products Industry Anc80 AAV gene therapy vector
  Industry 2 VTX-801 (Vivet Therapeutics)
Persons Person Combal, Jean-Philippe (Vivet Therapeutics 201705 CEO + Co-Founder before Gensight Biologics + Sanofi)
  Person 2 Gonzalez Aseguinolaza, Gloria (Vivet Therapeutics 201705 CSO + Co-Founder)
Region Region Paris
  Country France
  Street 29 rue Tronchet
  City 75008 Paris
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for »About Section«: Vivet Therapeutics SAS. (3/20/19). "Press Release: Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics". Paris & New York, NY.
Record changed: 2024-03-30


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Vívet Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px

» top